Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $329.00 Price Target at Barclays

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lifted by Barclays from $295.00 to $329.00 in a research note published on Friday morning, Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC restated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. Citigroup upped their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. Finally, Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday. Six analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $294.50.

Alnylam Pharmaceuticals Stock Up 2.7 %

Alnylam Pharmaceuticals stock opened at $273.91 on Friday. The company has a market capitalization of $35.16 billion, a PE ratio of -104.55 and a beta of 0.39. The firm’s fifty day moving average is $274.61 and its 200 day moving average is $226.42. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The company’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.15 EPS. Sell-side analysts expect that Alnylam Pharmaceuticals will post -2.74 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALNY. Allspring Global Investments Holdings LLC increased its stake in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares in the last quarter. Maryland State Retirement & Pension System boosted its holdings in Alnylam Pharmaceuticals by 4.1% in the 1st quarter. Maryland State Retirement & Pension System now owns 9,836 shares of the biopharmaceutical company’s stock worth $1,441,000 after buying an additional 385 shares during the period. Commonwealth Equity Services LLC boosted its holdings in Alnylam Pharmaceuticals by 32.3% in the 1st quarter. Commonwealth Equity Services LLC now owns 5,594 shares of the biopharmaceutical company’s stock worth $836,000 after buying an additional 1,365 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Alnylam Pharmaceuticals by 63.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 62,415 shares of the biopharmaceutical company’s stock valued at $9,328,000 after buying an additional 24,228 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its holdings in Alnylam Pharmaceuticals by 47.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company’s stock valued at $415,000 after acquiring an additional 892 shares during the period. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.